Open Access

Role of DNA mismatch repair genes in lung and head and neck cancer (Review)

  • Authors:
    • Sotirios G. Doukas
    • Dimitra P. Vageli
    • Taxiarchis Konstantinos Nikolouzakis
    • Luca Falzone
    • Anca Oana Docea
    • George Lazopoulos
    • Konstantinos Kalbakis
    • Aristidis Tsatsakis
  • View Affiliations

  • Published online on: September 3, 2019     https://doi.org/10.3892/wasj.2019.21
  • Pages: 184-191
  • Copyright: © Doukas et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The role of the DNA repair mechanism is to protect genetic material from destabilization. A defect in the DNA mismatch repair (MMR) mechanism has been associated with both hereditary and sporadic tumors. The dysregulation of MMR gene expression has been reported in lung, and in head and neck sporadic tumors. However, the mechanisms through which defects in the DNA MMR mechanism promote lung, and head and neck cancer remain unclear. Environmental factors and epigenetic alterations can significantly alter the ability of cells to repair genetic damage. The loss or a low expression of MMR genes allows for the survival of cells carrying a significant amount of genetic alterations, some in proto‑oncogenes or genes regulating the cell cycle. The dysregulation or malfunction of the MMR mechanism has also been linked to alterations in response to chemotherapy. The investigation of MMR dysregulations in lung, and head and neck carcinomas may contribute to a better understanding of their biological role in the development and progression of these types of cancer, and may thus also improve their diagnostic, prognostic and therapeutic value.

References

1 

Peltomäki P: DNA mismatch repair and cancer. Mutat Res. 488:77–85. 2001.PubMed/NCBI View Article : Google Scholar

2 

Peltomäki P: Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 21:1174–1179. 2003.PubMed/NCBI View Article : Google Scholar

3 

Li GM: DNA mismatch repair and cancer. Front Biosci. 8:d997–d1017. 2003.PubMed/NCBI View Article : Google Scholar

4 

Yang W: Structure and mechanism for DNA lesion recognition. Cell Res. 18:184–197. 2008.PubMed/NCBI View Article : Google Scholar

5 

Kolodner RD: Mismatch repair: Mechanisms and relationship to cancer susceptibility. Trends Biochem Sci. 20:397–401. 1995.PubMed/NCBI View Article : Google Scholar

6 

Jiricny J and Nyström-Lahti M: Mismatch repair defects in cancer. Curr Opin Genet Dev. 10:157–161. 2000.PubMed/NCBI View Article : Google Scholar

7 

Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin JP and Järvinen HJ: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 81:214–218. 1999.PubMed/NCBI View Article : Google Scholar

8 

Bohr VA: DNA repair fine structure and its relations to genomic instability. Carcinogenesis. 16:2885–2892. 1995.PubMed/NCBI View Article : Google Scholar

9 

Kruhøffer M, Jensen JL, Laiho P, Dyrskjøt L, Salovaara R, Arango D, Birkenkamp-Demtroder K, Sørensen FB, Christensen LL, Buhl L, et al: Gene expression signatures for colorectal cancer microsatellite status and HNPCC. Br J Cancer. 92:2240–2248. 2005.PubMed/NCBI View Article : Google Scholar

10 

Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomäki P, Sistonen P, Aaltonen LA, Nyström-Lahti M, et al: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 75:1215–1225. 1993.PubMed/NCBI View Article : Google Scholar

11 

Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M and Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:1027–1038. 1993.PubMed/NCBI View Article : Google Scholar

12 

Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopolous N, Peltomäki P, de la Chapelle A, Hamilton SR, et al: Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 9:48–55. 1995.PubMed/NCBI View Article : Google Scholar

13 

Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass J, Dunlop M, Wyllie A, Jessup JM, Peltomäki PT, et al: Mismatch repair gene analysis in HNPCC patients. Nat Med. 2:169–174. 1996.PubMed/NCBI View Article : Google Scholar

14 

Kowalski LD, Mutch DG, Herzog TJ, Rader JS and Goodfellow PJ: Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer. 18:219–227. 1997.PubMed/NCBI View Article : Google Scholar

15 

Chadwick RB, Pyatt RE, Niemann TH, Richards SK, Johnson CK, Stevens MW, Meek JE, Hampel H, Prior TW and de la Chapelle A: Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma. J Med Genet. 38:461–466. 2001.PubMed/NCBI View Article : Google Scholar

16 

Soliman PT and Lu K: Endometrial cancer associated with defective DNA mismatch repair. Obstet Gynecol Clin North Am. 34:701–715, viii. 2007.PubMed/NCBI View Article : Google Scholar

17 

Rosen DG, Cai KQ, Luthra R and Liu J: Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol. 19:1414–1420. 2006.PubMed/NCBI View Article : Google Scholar

18 

Vageli D, Daniil Z, Dahabreh J, Karagianni E, Vamvakopoulou DN, Ioannou MG, Scarpinato K, Vamvakopoulos NC, Gourgoulianis KI and Koukoulis GK: Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer. 64:282–288. 2009.PubMed/NCBI View Article : Google Scholar

19 

Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM and Chen CY: Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 111:887–895. 2003.PubMed/NCBI View Article : Google Scholar

20 

Xinarianos G, Liloglou T, Prime W, Sourvinos G, Karachristos A, Gosney JR, Spandidos DA and Field JK: p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. Int J Cancer. 101:248–252. 2002.PubMed/NCBI View Article : Google Scholar

21 

Kitajima Y, Miyazaki K, Matsukura S, Tanaka M and Sekiguchi M: Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer. Gastric Cancer. 6:86–95. 2003.PubMed/NCBI View Article : Google Scholar

22 

Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ. 157:327–349. 2004.PubMed/NCBI

23 

Nardone G, Rocco A and Budillon G: Molecular alteration of gastric carcinoma. Minerva Gastroenterol Dietol. 48:189–193. 2002.PubMed/NCBI

24 

El-Rifai W, Powell SM and EI-Rifai W: Molecular biology of gastric cancer. Semin Radiat Oncol. 12:128–140. 2002.PubMed/NCBI View Article : Google Scholar

25 

Sasaki S and Nakamura Y: Mutation of the mismatch repair genes for carcinogenesis of sporadic colorectal cancers with RER-positive phenotype. Nihon Rinsho. 54:1008–1013. 1996.(In Japanese). PubMed/NCBI

26 

Wallis Y and Macdonald F: The genetics of inherited colon cancer. Clin Mol Pathol. 49:M65–M73. 1996.PubMed/NCBI View Article : Google Scholar

27 

Burger M, Denzinger S, Hammerschmied CG, Tannapfel A, Obermann EC, Wieland WF, Hartmann A and Stoehr R: Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl). 84:833–841. 2006.PubMed/NCBI View Article : Google Scholar

28 

Kassem HS, Varley JM, Hamam SM and Margison GP: Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer. Br J Cancer. 84:321–328. 2001.PubMed/NCBI View Article : Google Scholar

29 

Leach FS, Hsieh JT, Molberg K, Saboorian MH, McConnell JD and Sagalowsky AI: Expression of the human mismatch repair gene hMSH2: A potential marker for urothelial malignancy. Cancer. 88:2333–2341. 2000.PubMed/NCBI

30 

Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A and Peltomäki P: Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol. 156:1773–1779. 2000.PubMed/NCBI View Article : Google Scholar

31 

Viale G, Trapani D and Curigliano G: Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. BioMed Res Int. 2017(4719194)2017.PubMed/NCBI View Article : Google Scholar

32 

Hsieh P and Yamane K: DNA mismatch repair: Molecular mechanism, cancer, and ageing. Mech Ageing Dev. 129:391–407. 2008.PubMed/NCBI View Article : Google Scholar

33 

Kijas AW, Studamire B and Alani E: Msh2 separation of function mutations confer defects in the initiation steps of mismatch repair. J Mol Biol. 331:123–138. 2003.PubMed/NCBI View Article : Google Scholar

34 

Gurin CC, Federici MG, Kang L and Boyd J: Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res. 59:462–466. 1999.PubMed/NCBI

35 

Hayashi M, Tamura G, Jin Z, Kato I, Sato M, Shibuya Y, Yang S and Motoyama T: Microsatellite instability in esophageal squamous cell carcinoma is not associated with hMLH1 promoter hypermethylation. Pathol Int. 53:270–276. 2003.PubMed/NCBI View Article : Google Scholar

36 

Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, Mariolis Sapsakos T, Papadakis GZ, Spandidos DA, Tsatsakis AM and Tsiaoussis J: Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). Oncol Rep. 39:2455–2472. 2018.(Review). PubMed/NCBI View Article : Google Scholar

37 

Lynch HT, Snyder CL, Shaw TG, Heinen CD and Hitchins MP: Milestones of Lynch syndrome 1895-2015. Nat Rev Canc. 15:181–194. 2015.PubMed/NCBI View Article : Google Scholar

38 

Antelo M, Golubicki M, Roca E, Mendez G, Carballido M, Iseas S, Cuatrecasas M, Moreira L, Sanchez A, Carballal S, et al: Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer. Int J Cancer. 145:705–713. 2019.PubMed/NCBI View Article : Google Scholar

39 

Carethers JM and Stoffel EM: Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. World J Gastroenterol. 21:9253–9261. 2015.PubMed/NCBI View Article : Google Scholar

40 

Adar T, Friedman M, Rodgers LH, Shannon KM, Zukerberg LR and Chung DC: Gastric cancer in Lynch syndrome is associated with underlying immune gastritis. J Med Genet. doi: 10.1136/jmedgenet-2018-105757 (Epub ahead of print). PubMed/NCBI View Article : Google Scholar

41 

Wang J, Greenberg S and Yates J: Lynch syndrome-associated upper tract urothelial carcinoma. Urology. 121:19–21. 2018.PubMed/NCBI View Article : Google Scholar

42 

Cloyd JM, Chun YS, Ikoma N, Vauthey JN, Aloia TA, Cuddy A, Rodriguez-Bigas MA and Nancy You Y: Clinical and genetic implications of DNA mismatch repair deficiency in biliary tract cancers associated with lynch syndrome. J Gastrointest Cancer. 49:93–96. 2018.PubMed/NCBI View Article : Google Scholar

43 

Anacleto C, Leopoldino AM, Rossi B, Soares FA, Lopes A, Rocha JC, Caballero O, Camargo AA, Simpson AJ and Pena SD: Colorectal cancer ‘methylator phenotype’: Fact or artifact? Neoplasia. 7:331–335. 2005.PubMed/NCBI

44 

Imai K and Yamamoto H: Carcinogenesis and microsatellite instability: The interrelationship between genetics and epigenetics. Carcinogenesis. 29:673–680. 2008.PubMed/NCBI View Article : Google Scholar

45 

Chang DK, Ricciardiello L, Goel A, Chang CL and Boland CR: Steady-state regulation of the human DNA mismatch repair system. J Biol Chem. 275:18424–18431. 2000.PubMed/NCBI View Article : Google Scholar

46 

Vageli DP, Zaravinos A, Daniil Z, Dahabreh J, Doukas SG, Spandidos DA, Gourgoulianis KI and Koukoulis GK: hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: Correlation with patient survival and response to adjuvant chemotherapy treatment. Int J Biol Markers. 27:e400–e404. 2013.PubMed/NCBI View Article : Google Scholar

47 

Vageli DP, Giannopoulos S, Doukas SG, Kalaitzis C, Giannakopoulos S, Giatromanolaki A, Koukoulis GK and Touloupidis S: Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium. Oncol Lett. 5:283–294. 2013.PubMed/NCBI View Article : Google Scholar

48 

Vageli DP, Doukas SG and Markou A: Mismatch DNA repair mRNA expression profiles in oral melanin pigmentation lesion and hamartomatous polyp of a child with Peutz-Jeghers syndrome. Pediatr Blood Cancer. 60:E116–E117. 2013.PubMed/NCBI View Article : Google Scholar

49 

Vageli DP, Papamichali R, Kambosioras K, Papandreou CN and Koukoulis GK: Mismatch DNA repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in colorectal carcinomas. J Genet Syndr Gene Ther. View Article : Google Scholar

50 

Christmann M and Kaina B: Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. J Biol Chem. 275:36256–36262. 2000.PubMed/NCBI View Article : Google Scholar

51 

Strathdee G, MacKean MJ, Illand M and Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 18:2335–2341. 1999.PubMed/NCBI View Article : Google Scholar

52 

Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB and Boland CR: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 117:123–131. 1999.PubMed/NCBI View Article : Google Scholar

53 

Bhattacharjee P, Sanyal T, Bhattacharjee S and Bhattacharjee P: Epigenetic alteration of mismatch repair genes in the population chronically exposed to arsenic in West Bengal, India. Environ Res. 163:289–296. 2018.PubMed/NCBI View Article : Google Scholar

54 

Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G and Libra M: Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers (Basel). 11(E38)2019.PubMed/NCBI View Article : Google Scholar

55 

Banna GL, Torino F, Marletta F, Santagati M, Salemi R, Cannarozzo E, Falzone L, Ferraù F and Libra M: Lactobacillus rhamnosus GG: An Overview to explore the rationale of its use in cancer. Front Pharmacol. doi: 10.3389/fphar.2017.00603. PubMed/NCBI View Article : Google Scholar

56 

Westwood A, Glover A, Hutchins G, Young C, Brockmoeller S, Robinson R, Worrilow L, Wallace D, Rankeillor K, Adlard J, et al: Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation. J Clin Pathol. 72:443–447. 2019.PubMed/NCBI View Article : Google Scholar

57 

Kang Z, Zhu Y, Zhang QA, Dong L, Xu F, Zhang X and Guan M: Methylation and expression analysis of mismatch repair genes in extramammary Paget's disease. J Eur Acad Dermatol Venereol. 33:874–879. 2019.PubMed/NCBI View Article : Google Scholar

58 

Mäki-Nevala S, Valo S, Ristimäki A, Sarhadi V, Knuutila S, Nyström M, Renkonen-Sinisalo L, Lepistö A, Mecklin JP and Peltomäki P: DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression. EBioMedicine. 39:280–291. 2019.PubMed/NCBI View Article : Google Scholar

59 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar

60 

Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. Cancer Lett. 300:10–19. 2011.PubMed/NCBI View Article : Google Scholar

61 

Falzone L, Lupo G, La Rosa GRM, Crimi S, Anfuso CD, Salemi R, Rapisarda E, Libra M and Candido S: Identification of novel microRNAs and their diagnostic and prognostic significance in oral cancer. Cancers (Basel). 11(E610)2019.PubMed/NCBI View Article : Google Scholar

62 

Hafsi S, Candido S, Maestro R, Falzone L, Soua Z, Bonavida B, Spandidos DA and Libra M: Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. Oncol Lett. 11:1021–1025. 2016.PubMed/NCBI View Article : Google Scholar

63 

Falzone L, Romano GL, Salemi R, Bucolo C, Tomasello B, Lupo G, Anfuso CD, Spandidos DA, Libra M and Candido S: Prognostic significance of deregulated microRNAs in uveal melanomas. Mol Med Rep. 19:2599–2610. 2019.PubMed/NCBI View Article : Google Scholar

64 

Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, Torino F, Signorelli SS, Montella M and Libra M: Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget. 7:72758–72766. 2016.PubMed/NCBI View Article : Google Scholar

65 

Costa PM and Pedroso de Lima MC: MicroRNAs as molecular targets for cancer therapy: On the modulation of microRNA expression. Pharmaceuticals (Basel). 6:1195–1220. 2013.PubMed/NCBI View Article : Google Scholar

66 

McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L, et al: Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 8:14221–14250. 2017.PubMed/NCBI View Article : Google Scholar

67 

Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000.PubMed/NCBI View Article : Google Scholar

68 

Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33:1290–1297. 2005.PubMed/NCBI View Article : Google Scholar

69 

Sasaki CT, Doukas SG and Vageli DP: In vivo short-term topical application of BAY 11-7082 prevents the acidic bile-induced mRNA and miRNA oncogenic phenotypes in exposed murine hypopharyngeal mucosa. Neoplasia. 20:374–386. 2018.PubMed/NCBI View Article : Google Scholar

70 

Doukas SG, Vageli DP and Sasaki CT: NF-κB inhibition reverses acidic bile-induced miR-21, miR-155, miR-192, miR-34a, miR-375 and miR-451a deregulations in human hypopharyngeal cells. J Cell Mol Med. 22:2922–2934. 2018.PubMed/NCBI View Article : Google Scholar

71 

Doukas PG, Vageli DP, Doukas SG and Sasaki CT: Temporal characteristics of NF-κB inhibition in blocking bile-induced oncogenic molecular events in hypopharyngeal cells. Oncotarget. doi: https://doi.org/10.18632/oncotarget.26917. PubMed/NCBI View Article : Google Scholar

72 

Landau DA and Slack FJ: MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin Oncol. 38:743–751. 2011.PubMed/NCBI View Article : Google Scholar

73 

Mao G, Lee S, Ortega J, Gu L and Li GM: Modulation of microRNA processing by mismatch repair protein MutLα. Cell Res. 22:973–985. 2012.PubMed/NCBI View Article : Google Scholar

74 

Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, et al: Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA. 107:6982–6987. 2010.PubMed/NCBI View Article : Google Scholar

75 

Zhong Z, Dong Z, Yang L, Chen X and Gong Z: MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol. 34:1959–1965. 2013.PubMed/NCBI View Article : Google Scholar

76 

Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, Ascierto PA, Libra M and Candido S: MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAFV600E mutation detected in circulating-free DNA. Front Pharmacol. Aug 14 2018 (Epub ahead of print) doi: 10.3389/fphar.2018.00856. PubMed/NCBI View Article : Google Scholar

77 

Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 21:7435–7451. 2002.PubMed/NCBI View Article : Google Scholar

78 

Zhong Y, Carmella SG, Upadhyaya P, Hochalter JB, Rauch D, Oliver A, Jensen J, Hatsukami D, Wang J, Zimmerman C, et al: Immediate consequences of cigarette smoking: Rapid formation of polycyclic aromatic hydrocarbon diol epoxides. Chem Res Toxicol. 24:246–252. 2011.PubMed/NCBI View Article : Google Scholar

79 

Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE, Voiculescu V, et al: Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol. 52:637–655. 2018.PubMed/NCBI View Article : Google Scholar

80 

Dylawerska A, Barczak W, Wegner A, Golusinski W and Suchorska WM: Association of DNA repair genes polymorphisms and mutations with increased risk of head and neck cancer: A review. Med Oncol. 34(197)2017.PubMed/NCBI View Article : Google Scholar

81 

Demokan S, Suoglu Y, Demir D, Gozeler M and Dalay N: Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer. Ann Oncol. 17:995–999. 2006.PubMed/NCBI View Article : Google Scholar

82 

Wang Y, Irish J, MacMillan C, Brown D, Xuan Y, Boyington C, Gullane P and Kamel-Reid S: High frequency of microsatellite instability in young patients with head-and-neck squamous-cell carcinoma: Lack of involvement of the mismatch repair genes hMLH1 and hMSH2. Int J Cancer. 93:353–360. 2001.PubMed/NCBI View Article : Google Scholar

83 

Liu K, Huang H, Mukunyadzi P, Suen JY, Hanna E and Fan CY: Promoter hypermethylation: An important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 126:548–553. 2002.PubMed/NCBI View Article : Google Scholar

84 

Murata H, Khattar NH, Kang Y, Gu L and Li GM: Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene. 21:5696–5703. 2002.PubMed/NCBI View Article : Google Scholar

85 

Demokan S, Muslumanoglu M, Yazici H, Igci A and Dalay N: Investigation of microsatellite instability in Turkish breast cancer patients. Pathol Oncol Res. 8:138–141. 2002.PubMed/NCBI

86 

Ruszkiewicz A, Bennett G, Moore J, Manavis J, Rudzki B, Shen L and Suthers G: Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology. 34:541–547. 2002.PubMed/NCBI View Article : Google Scholar

87 

Shia J, Ellis NA and Klimstra DS: The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch. 445:431–441. 2004.PubMed/NCBI View Article : Google Scholar

88 

Pereira CS, Oliveira MV, Barros LO, Bandeira GA, Santos SH, Basile JR, Guimarães AL and De Paula AM: Low expression of MSH2 DNA repair protein is associated with poor prognosis in head and neck squamous cell carcinoma. J Appl Oral Sci. 21:416–421. 2013.PubMed/NCBI View Article : Google Scholar

89 

Nogueira GA, Lourenço GJ, Oliveira CB, Marson FA, Lopes-Aguiar L, Costa EF, Lima TR, Liutti VT, Leal F, Santos VC, et al: Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma. Int J Cancer. 137:810–818. 2015.PubMed/NCBI View Article : Google Scholar

90 

Jha R, Gaur P, Sharma SC and Das SN: Single nucleotide polymorphism in hMLH1 promoter and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Gene. 526:223–227. 2013.PubMed/NCBI View Article : Google Scholar

91 

Liu K, Huang H, Mukunyadzi P, Suen JY, Hanna E and Fan CY: Promoter hypermethylation: An important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 126:548–553. 2002.PubMed/NCBI View Article : Google Scholar

92 

Liu K, Zuo C, Luo QK, Suen JY, Hanna E and Fan CY: Promoter hypermethylation and inactivation of hMLH1, a DNA mismatch repair gene, in head and neck squamous cell carcinoma. Diagn Mol Pathol. 12:50–56. 2003.PubMed/NCBI

93 

Zuo C, Zhang H, Spencer HJ, Vural E, Suen JY, Schichman SA, Smoller BR, Kokoska MS and Fan CY: Increased microsatellite instability and epigenetic inactivation of the hMLH1 gene in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 141:484–490. 2009.PubMed/NCBI View Article : Google Scholar

94 

Tawfik HM, El-Maqsoud NM, Hak BH and El-Sherbiny YM: Head and neck squamous cell carcinoma: Mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene. Am J Otolaryngol. 32:528–536. 2011.PubMed/NCBI View Article : Google Scholar

95 

Xinarianos G, Liloglou T, Prime W, Maloney P, Callaghan J, Fielding P, Gosney JR and Field JK: hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res. 60:4216–4221. 2000.PubMed/NCBI

96 

Hsu HS, Wen CK, Tang YA, Lin RK, Li WY, Hsu WH and Wang YC: Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res. 11:5410–5416. 2005.PubMed/NCBI View Article : Google Scholar

97 

Kanellis G, Chatzistamou I, Koutselini H, Politi E, Gouliamos A, Vlahos L and Koutselinis A: Expression of DNA mismatch repair gene MSH2 in cytological material from lung cancer patients. Diagn Cytopathol. 34:463–466. 2006.PubMed/NCBI View Article : Google Scholar

98 

Downey CM and Jirik FR: DNA mismatch repair deficiency accelerates lung neoplasm development in K-ras(LA1/+) mice: A brief report. Cancer Med. 4:897–902. 2015.PubMed/NCBI View Article : Google Scholar

99 

Scartozzi M, Franciosi V, Campanini N, Benedetti G, Barbieri F, Rossi G, Berardi R, Camisa R, Silva RR, Santinelli A, et al: Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 53:103–109. 2006.PubMed/NCBI View Article : Google Scholar

100 

Takahashi Y, Kondo K, Hirose T, Nakagawa H, Tsuyuguchi M, Hashimoto M, Sano T, Ochiai A and Monden Y: Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate-exposed workers. Mol Carcinog. 42:150–158. 2005.PubMed/NCBI View Article : Google Scholar

101 

Falzone L, Salomone S and Libra M: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. doi: doi.org/10.3389/fphar.2018.01300. PubMed/NCBI View Article : Google Scholar

102 

Fink D, Nebel S, Norris PS, Aebi S, Kim HK, Haas M and Howell SB: The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer. 77:703–708. 1998.PubMed/NCBI View Article : Google Scholar

103 

Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC and Chaney SG: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 58:3579–3585. 1998.PubMed/NCBI

104 

Hause RJ, Pritchard CC, Shendure J and Salipante SJ: Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 22:1342–1350. 2016.PubMed/NCBI View Article : Google Scholar

105 

Microsatellite Instability-Defective DNA Mismatch Repair: ESMO Biomarker Factsheet. [urihttps://oncologypro.esmo.org/Education-Library/Factsheets-on-Biomarkers/Microsatellite-Instability-Defective-DNA-Mismatch-Repair#eztoc1701983_0_0_8/simplehttps://oncologypro.esmo.org/Education-Library/Factsheets-on-Biomarkers/Microsatellite-Instability-Defective-DNA-Mismatch-Repair#eztoc1701983_0_0_8/.

106 

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS and Gulley JL: Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 6(35)2018.PubMed/NCBI View Article : Google Scholar

107 

Chang L, Chang M, Chang HM and Chang F: Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl Immunohistochem Mol Morphol. 26:e15–e21. 2018.PubMed/NCBI View Article : Google Scholar

108 

Zhao P, Li L, Jiang X and Li Q: Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 12(54)2019.PubMed/NCBI View Article : Google Scholar

109 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: KEYNOTE-001 Investigators: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.PubMed/NCBI View Article : Google Scholar

110 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 375:1823–1833. 2016.PubMed/NCBI View Article : Google Scholar

111 

Pylkkänen L, Karjalainen A, Anttila S, Vainio H and Husgafvel-Pursiainen K: No evidence of microsatellite instability but frequent loss of heterozygosity in primary resected lung cancer. Environ Mol Mutagen. 30:217–223. 1997.PubMed/NCBI

112 

Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB and Sidransky D: Frequent microsatellite instability in primary small cell lung cancer. Cancer Res. 54:2098–2101. 1994.PubMed/NCBI

113 

Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F and Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA. 91:9871–9875. 1994.PubMed/NCBI View Article : Google Scholar

114 

Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C and Anker P: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 2:1033–1035. 1996.PubMed/NCBI View Article : Google Scholar

115 

Hansen LT, Thykjaer T, Ørntoft TF, Rasmussen LJ, Keller P, Spang-Thomsen M, Edmonston TB, Schmutte C, Fishel R and Petersen LN: The role of mismatch repair in small-cell lung cancer cells. Eur J Cancer. 39:1456–1467. 2003.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

July 2019
Volume 1 Issue 4

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Doukas, S.G., Vageli, D.P., Nikolouzakis, T.K., Falzone, L., Docea, A.O., Lazopoulos, G. ... Tsatsakis, A. (2019). Role of DNA mismatch repair genes in lung and head and neck cancer (Review). World Academy of Sciences Journal, 1, 184-191. https://doi.org/10.3892/wasj.2019.21
MLA
Doukas, S. G., Vageli, D. P., Nikolouzakis, T. K., Falzone, L., Docea, A. O., Lazopoulos, G., Kalbakis, K., Tsatsakis, A."Role of DNA mismatch repair genes in lung and head and neck cancer (Review)". World Academy of Sciences Journal 1.4 (2019): 184-191.
Chicago
Doukas, S. G., Vageli, D. P., Nikolouzakis, T. K., Falzone, L., Docea, A. O., Lazopoulos, G., Kalbakis, K., Tsatsakis, A."Role of DNA mismatch repair genes in lung and head and neck cancer (Review)". World Academy of Sciences Journal 1, no. 4 (2019): 184-191. https://doi.org/10.3892/wasj.2019.21